🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer Now fully published NEJM doi.org/10.1056/NEJMoa… 👉irTRAEs ≥ 3°: 4% 👉95% major pathological response 👉68% pathological complete response 👏just impressive... ESMO - Eur. Oncology

Team Tübingen at #DEGRO24.

Inspiring talk by Petra van Houdt nki about quantitative #MRI in #radiotherapy. Technical validation on the #MRL fruitful and ongoing and important open source initiatives out there. Thx for visiting Uniklinikum Tübingen! #medphys

Online First: Adaptive #radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell #lungcancer, according to [18F]FDG-PET uptake (RTEP7–IFCT-1402): a multicentre, randomised, controlled, phase 2 trial thelancet.com/journals/lanon…

A day in the life of an editor in chief... @ctro_journal #radonc

Archery - #1 sport NOT to do during your summer vacation if you are a #RadOnc and actually don’t want to think about random and systematic errors for 2 weeks… (but hey- not bad for a for attempt after a 15 year break??)

Online First: #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study #radonc thelancet.com/journals/lanon…

Fantastic data - we implemented this treatment immediately after the results were presented at ASCO GI and are impressed by the outcomes. Congrats to Laura Dawson !!!!

ADRIATIC is a practice changing trial for LS-SCLC with consolidation durvalumab after chemo radiation demonstrating superior progression free and overall survival over chemo radiation alone. A long awaited change in standard of care! Another win for lung cancer patients.

Applicability of adaptive trials design and platform studies - tips from the amazing Saskia Litiere #ESMO24 EORTC AACR ESMO - Eur. Oncology OncoAlert #OncoAlert #clinicaltrial

Real-world data on DPYD activity in the context of radiotherapy. Here is our institutional data published by #ElginHoffmann from UKT Radiation Oncology #radonc 🔹8% with decreased DPYD activity 🔹No increased toxicity after dose adjustment pubmed.ncbi.nlm.nih.gov/39230592/

What attending my first tumor board was like #radonc

ASTRO abstracts are no longer embargoed after 5PM EST 9/27. Here is LBA1: PARTIQoL, Phase III study of protons vs IMRT for LR/IR prostate cancer. No significant differences in tumor control or patient-reported quality of life out to 60 months of follow up. #radonc

ctro.science/article/S2405-…

ctro.science/article/S2405-…

ctro.science/article/S2405-…

What a great day! Yesterday we went live with Comprehensive Motion Management for our MR-Linac! Thanks to everybody who made this possible! Simon Boeke Marcel Nachbar @D_Thorwarth Max Niyazi Monica Lo Russo Elekta MR-Linac Consortium DFG

Top Clinical Trials at ESTRO 2025: Organ Preservation and Quality of life after Total Neoadjuvant Therapy for LA Rectal Cancer Cihan Gani oncodaily.com/science/estro-… #Cancer #CancerResearch #Medicine #Health #MedX #MedNews #MedEd #RectalCancer #TotalNeoadjuvantTherapy #Oncology